CLASSIC 5-year follow-up: adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy
Five years on, the benefit of adjuvant capecitabine and oxaliplatin held and translated into longer survival: 78 percent alive against 69 percent with surgery alone.
Overview
Five-year follow-up of the CLASSIC trial (1,035 patients) at a median of 62.4 months: disease-free survival events in 27 percent of chemotherapy patients against 39 percent of observation patients (hazard ratio 0.58); estimated five-year disease-free survival 68 against 53 percent and overall survival 78 against 69 percent (hazard ratio 0.66).
- Five-year disease-free survival 68 percent (95% CI 63 to 73) versus 53 percent (47 to 58); hazard ratio 0.58 (0.47 to 0.72).
- Five-year overall survival 78 percent (74 to 82) versus 69 percent (64 to 73); hazard ratio 0.66 (0.51 to 0.85), p 0.0015.
Confirms a survival benefit for adjuvant CAPOX after D2 gastrectomy.
- Adverse event data were not collected after the primary analysis.
Similar pages
not linked directly; found by shared links- Key paperCLASSIC: adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy
Shares CLASSIC, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
- TrialA Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
- TrialA Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
- TrialStudy to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
- TrialA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
- TrialA Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
Shares Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer.
- TrialA Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Shares Oxaliplatin, Capecitabine.
- TrialA Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Shares Oxaliplatin, Capecitabine.